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Secondary mitral regurgitation (sMR) is characterized by left ventricular (LV) dilatation
or dysfunction, resulting in failure of mitral leaflet coaptation. sMR complicates up to
35% of ischaemic cardiomyopathies (1) and 57% of dilated cardiomyopathies (2). Due
to the prevalence of coronary artery disease worldwide, ischaemic cardiomyopathy is
the most frequently encountered cause of sMR in clinical practice. Although mortality
from cardiovascular disease has gradually fallen in Western countries, severe sMR
remains an independent predictor of mortality (3) and hospitalization for heart failure
(4). The presence of even mild sMR following acute MI reduces long-term survival
free of major adverse events (1). Such adverse outcomes worsen as the severity of
sMR increases, due to a cycle in which LV remodeling begets sMR and vice versa.
Current guidelines do not recommend invasive treatment of the sMR alone as a first-line
approach, due to the paucity of evidence supporting improvement in clinical outcomes.
Furthermore, a lack of international consensus on the thresholds that define severe
sMR has resulted in confusion amongst clinicians determining whether intervention is
warranted (5, 6). The recent Cardiovascular Outcomes Assessment of the MitraClip
Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation
(COAPT) trial (7) assessing the effectiveness of transcatheter mitral valve repair is the first
study to demonstrate mortality benefit from correction of sMR and has reignited interest
in identifying patients who would benefit from mitral valve intervention. Multimodality
imaging, including echocardiography and cardiovascular magnetic resonance (CMR),
plays a key role in helping to diagnose, quantify, monitor, and risk stratify patients for
surgical and transcatheter mitral valve interventions.
Keywords: mitral regurgitation, echocardiogaphy, magnetic resonanace imaging, computed tomography,
ischaemic heart disease
INTRODUCTION
Mitral regurgitation (MR) is the most common valvular disease, and prevalence is increasing with
improved life expectancy in the Western world (8). Primary MR (pMR) is due to a structural or
degenerative disorder of the valve apparatus with left ventricular (LV) impairment or dilatation
resulting from the regurgitation. Conversely in secondary MR (sMR), the mitral apparatus is
relatively normal and failure of leaflet coaptation is directly attributable to a diseased LV which
is subject to contractile impairment and/or pathogenic dilatation. sMR is observed in up to 35% of
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patients with ischaemic cardiomyopathy (ICM) due to post-
infarct LV remodeling (1, 9) and 57% of patients with
dilated cardiomyopathy (DCM) (2). Although sMR occurs more
frequently in patients with DCM, ICM is the most prevalent
form of cardiovascular disease worldwide and therefore is the
most common cause of sMR. The presence of even mild sMR
adversely impacts prognosis from time of onset (1, 2). Therefore,
early diagnosis, careful monitoring and timely intervention are
critical. The aim of this article is to outline the advantages
and disadvantages of echocardiography, cardiovascular magnetic
resonance (CMR) and computer tomography (CT) in the
management of sMR.
PATHOPHYSIOLOGY OF sMR
Normal function of the mitral valve (MV) relies on leaflet
coaptation during ventricular systole. This requires undistorted
LV geometry, intact MV apparatus, synchronous contraction
of papillary muscles and a balance between opening and
closing forces generated by LV contraction and relaxation.
Failure of any of these processes results in sMR, although the
mechanism depends on the insult to the LV. For example, an
inferolateral myocardial infarction may cause focal myocardial
remodeling and an akinetic superolateral papillary muscle,
leading to asymmetric chordal traction on posterior and
anterior leaflets, apical displacement of the coaptation point
and ultimately eccentric, posteriorly directed MR (Carpentier
type IIIb mechanism). Less frequently, symmetric dilatation
of the LV occurs due to dilated cardiomyopathy (DCM) or
severe 3-vessel coronary disease, leading to symmetric annular
dilatation, equal papillary muscle displacement, and tenting of
both leaflets resulting in a central jet of regurgitation (Carpentier
type Ia mechanism) (Figure 1).
A vicious cycle ensues in which the resultant sMR causes
left atrial and ventricular volume overload and dilatation,
which in turn promotes further sMR (Figure 2). Chronic severe
sMR results in compensatory left atrial (LA) and ventricular
dilatation and eventual dysfunction. Over time, reduced chamber
compliance results in pulmonary venous hypertension and
ultimately right ventricular pressure overload.
DIAGNOSIS AND IDENTIFYING ETIOLOGY
Reliance on clinical examination to detect sMR lacks sensitivity,
and the main diagnostic tool is transthoracic echocardiography
(TTE) with color flow doppler. On finding MR, the role of
the imager is to determine the mechanism of MR, through
the assessment of the mitral leaflets, annulus, chordae and
papillary muscles, along with associated changes in the ventricle
and atrium.
Imaging the Mitral Leaflets
Although the classical definition of sMR requires that the MV
leaflets are normal, it is now known that changes occur in
response to the stresses exerted upon the tented leaflets that
counteract the loss of leaflet coaptation. These compensatory
changes include progressive leaflet lengthening, thickening and
fibrosis (10, 11). 2D TTE using fundamental imaging is the main
modality for anatomic assessment of leaflet thickness (normal or
increased), motion (normal, restricted or increased) and presence
and distribution of calcification (none, mild, moderate, severe).
3D TTE adds incremental value in providing a comprehensive
assessment of the entire valve, including the ability to identify
the specific scallop(s) involved. 3D TOE however, is the gold-
standard method for full assessment of the valve and scallops
compared to surgical findings, and offers dynamic quantification
of leaflet geometry throughout the cardiac cycle (12). Leaflet
configuration can influence likelihood of successful surgical
repair. The following configurations are shown to be predictors
of failure of repair: Leaflet coaptation distance > 1 cm, tenting
height> 6mm, tenting area> 2.5 cm2 on TTE and> 1.6 cm2 on
TOE and posterior leaflet angle > 45◦. A full summary of these
factors are categorized in Table 1. If these factors are present, this
may influence the decision re: mitral valve repair vs. replacement
or whether intervention should proceed at all (Figure 3).
In patients with poor acoustic windows or who are unable
to tolerate TOE, CMR and ECG-gated CT both offer good
alternatives for visualizing leaflet anatomy and quantitative
assessment of MR, but lack the 3D views that are extremely
helpful for the dynamic assessment of scallops. Nevertheless,
CT provides useful measurements in sMR that correlate with
3D echo including open mitral valve leaflet area (R2 = 0.97;
P < 001), closed mitral leaflet area (R2 = 0.84; P < 0.01),
tenting area and volume (R2 = 0.84), and papillary muscle
tethering distances (superolateral R2 = 0.90; inferoseptal R2
= 0.84) (30). CT is also the best method to localize and
quantify calcification in and around the MV apparatus, a role
which is likely to grow with the use of transcatheter mitral
valve repair (TMVR). CMR has lower temporal resolution
compared to echocardiography but has high spatial resolution
that provides a good alternative modality for defining leaflet
anatomy, including individual scallops (31), which compares well
to 2D TOE (32).
Imaging the Mitral Annulus
The normal mitral annulus is elliptical shaped in cross-section
and saddle-shaped in 3 dimensions. The highest points are near
the superolateral commissure while the lowest points are located
at the base of P2 and P3 (33). The annulus changes configuration
throughout the cardiac cycle to maintain leaflet coaptation,
from D-shaped in mid-systole to a more circular shape in early
diastole, reducing annular area by 20–30% across the cardiac
cycle. The annulus also moves away from the apex of the heart in
diastole, although motion of the posterior aspect is more marked
than the anterior annulus, and there is conformational change
with accentuation of the saddle shape in systole. All of these
movements are affected by ischaemia, which tends to reduce
the dynamic change in area, impair longitudinal motion, and
flatten the annulus, leading to increased leaflet stress (34–37). The
extent of remodeling is greater following anterior compared to
inferior myocardial infarction (MI) (38). These changes can be
tracked by high spatial and temporal resolution imaging using
3D TOE. Figure 4 is an example of a 3D reconstructed model
at end-diastole and end-systole, although annular parameters
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FIGURE 1 | Difference between asymmetrical (A,B) and symmetrical (C,D) LV remodeling on MR jet direction on 2D TOE.
can be tracked for each frame acquired through the cardiac
cycle. 2D measurements, whether by TTE or TOE, are only an
approximation, since accurate alignment to themajor axes is only
possible with multi-planar imaging. Using the parasternal long
axis view on 2D TTE (or left ventricular outflow tract view on
CMR), the mitral annulus is considered dilated if the diastolic
ratio of annulus/anterior leaflet is > 1.3, or if the absolute
annulus diameter is > 3.5 cm (27). The upper reference limit
of normal for indexed mitral annulus area by 3D TOE is 6.9
cm2/m2 (39). While 3D TTE and TOE are gold standard, there
is increasing evidence supporting the use of ECG-synchronized
3D multi-detector CT in the planning of TMVR, particularly for
assessing annulus dimensions, landing zones, alignment with the
inter-commissural lines for coaxial deployment and prevention
of LVOT obstruction (40).
Imaging the Subvalvular Apparatus
Normal functioning of the subvalvular apparatus is intimately
linked to the LV and can have a profound impact on the
severity of sMR. There is a higher incidence of sMR in
patients with inferior than anterior myocardial infarction (MI)
despite less severe LV remodeling with the former. This is due
to localized inferobasal LV remodeling following inferior MI,
resulting in displacement of the contiguous papillary muscle
(38, 41, 42). Note should be drawn to recent autopsy data
supporting a change in terminology in relation to the papillary
muscles, from posteromedial to inferoseptal, and anterolateral
to superolateral (43, 44). The extent of papillary muscle
displacement is best evaluated on 3D TOE or CMR. The most
important measurements include the interpapillary distance
and posterior papillary-fibrosa distance. Interpapillary muscle
distance >2 cm and posterior papillary-fibrosa distance >4 cm
are considered to be unfavorable characteristics for MV repair
(Figure 5) (27).
Direct papillary muscle infarction (PMI) also contributes to
sMR in up to a third of patients following acute MI. Late
gadolinium enhancement (LGE) of the papillary muscles on
CMR can diagnose PMI but the prognostic significance of these
findings are unclear (45, 46). Following 1–3% of acute MI,
infarctions of papillary muscles or chordae tendineae can lead
to rupture, leading to flail mitral leaflets and severe valvular
incompetence (47). If left untreated, in-hospital mortality
approaches 80% (48). TTE is often used in the acute setting to
confirm clinical suspicion of acute severe MR but TOE is usually
required to elucidate the mechanism, due to the superior imaging
of the subvalvular apparatus.
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FIGURE 2 | Relationship of LV remodeling with sMR.
Imaging the Left Ventricle
The presence of sMR increases the poor prognosis of reduced
ventricular function, and the frequency and severity of adverse
outcomes increase as the MR worsens. Heart failure affects the
majority of patients with sMR within 5 years, including those
who have normal LVEF (49). The interaction between sMR and
LV size and function is therefore a critical component of multi-
modality imaging assessment; the purpose of which, is to define
anatomy and pathophysiology of the MR, determine prognosis
and select patients suitable for intervention.
Transthoracic echocardiography (TTE) is usually the first line
investigation for the investigation of LV size and function by 2D
Simpson’s biplane method. 3D volumetric assessment is more
accurate and reproducible (50) but under-estimates volumes,
even with the use of contrast, compared to the gold-standard
CMR methods (51–53). In severe compensated sMR, LV systolic
function is hyperdynamic due to the Frank-Starling mechanism.
This can give a false impression of the true impairment of LVEF.
Measurement of global longitudinal strain (GLS) with speckle
tracking provides a less load-dependent method of assessing
LV function, but is not currently routinely acquired. Greater
impairment of GLS is associated with higher mortality and is
an independent predictor of long-term outcome in patients with
chronic ischaemic cardiomyopathy (50). Furthermore, in a study
of 650 patients with severe sMR, GLS was shown to be an
independent predictor of all-cause mortality, while LVEF was not
(54). Stress echocardiography provides additional information
where there is a discrepancy between patient symptoms and
resting severity of MR by detecting those in whom sMR worsens
with exercise. In such patients, a blunted LVEF response to
exercise (mean increase of 5 vs. 10%) and an effective regurgitant
orifice area (EROA) increase > 0.13 cm2 are independent
predictors of pulmonary oedema (55) and cardiac mortality
(15), respectively.
CMR is not only the gold standard for measuring LV structure
(EDV, mass/volume ratio) and function (LVEF; ESV) but also
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TABLE 1 | Pre-operative predictors of recurrence of sMR following surgical mitral
valve repair.
Pre-operative predictors of failure of surgical mitral valve repair in sMR
Modality Accuracy Reference
MITRAL VALVE











Leaflet tenting height >
6mm
TTE N/A (22)









PPV 92% NPV 100%
(21)























EDD > 6.5 cm TTE N/A (21, 22, 24)
ESD > 5.1 cm TTE N/A (21)










distance > 4 cm
TTE N/A (27)

























MR, Mitral Regurgitation; TTE, Transthoracic Echocardiogram; TOE, Transoesophageal
Echocardiogram; CMR, Cardiovascular Magnetic Resonance; EDD, End-Diastolic
Diameter; ESD, End-Systolic Diameter; ESV, End Systolic Volume.
quantifies pathophysiological changes in the myocardium. CMR
measures the presence, extent and location of post-infarction
scar using LGE and thereby identifies those with greater risk
of sMR (56) and higher mortality in those undergoing surgery
(3). Furthermore, CMR can quantify diffuse interstitial fibrosis
in the form of extracellular volume (ECV) using T1 mapping.
In sMR, ECV expansion may occur secondary to the MR
or the underlying LV pathology. Although increased T1 and
ECV are important predictors of outcome in IHD (57), with
incremental predictive value to LVEF and LGE (56), to date, there
are no data on the relative importance of ECV expansion vs.
volume overload in sMR, nor on the ability of ECV to predict
outcomes in sMR.
Summary Recommendations
• 2D and 3D assessment by TTE supplemented by TOE are
the investigations of choice for imaging the pathognomonic
changes to the mitral leaflets, annulus, chordae and papillary
muscles in ischaemic sMR.
• CMR or CT assessment of the valve is useful if adequate
imaging is not obtained with echocardiography (Figure 6).
• LV volumetric assessment by 3D echo is superior to 2D
echo, however, CMR is the gold-standard technique to assess
the LV due to superior spatial resolution, allowing accurate
measurement of LV volume, geometry, fibrosis and extent
of scar.
QUANTIFYING SEVERITY OF sMR
Role of Echocardiography
Current European and American guidelines recommend an
integrated approach to the assessment of sMR, in part
recognizing the limitations of individual qualitative, semi-
quantitative, and quantitative echocardiographic parameters and
in part understanding that not every measurement can be made
in all patients (5, 58). Although TTE is the first-line investigation
for sMR (27), quantifying severity is much more difficult than
in primary MR for several reasons. Firstly, LV stroke volume is
often reduced by the impact of IHD, which means that the RVol
in sMR is often smaller than in pMR. There is disagreement
between European and US guidelines on the size of RVol in
severe sMR, although evidence supports an adverse prognostic
outcome at an RVol >30ml (18). Secondly, the shape of the
regurgitant orifice is often altered in sMR from a hemisphere
to an ellipse, meaning that quantification using measures such
as vena contracta width (VCW) and flow convergence is not
as reliable as in primary MR. These individual measures do
however retain diagnostic and prognostic utility Table 2. For
example, in a study of 356 patients with severe sMR, VCW
> 0.4 cm on TTE predicted the combined endpoint of death,
HF hospitalization and treatment (16). Thirdly, haemodynamic
status, LV end-diastolic pressure and left atrial pressure may
be profoundly altered by the effects of IHD, which in turn
can all alter measures of sMR severity, independent of the size
of the regurgitant orifice. For example, although a jet of sMR
on color Doppler > 4.5 cm2 or > 50% of the LA area is
associated with increased mortality at 1 year (OR 4.47 cf mild
or absent MR) (14), this is not a recommended way of assessing
severity of regurgitation because jet area is so dependent on
haemodynamic status. Likewise, blunting or reversal of the S
wave on pulmonary venous flow pattern on pulse Doppler in
sMR may occur simply due to high LVEDP and LA pressure,
independent of the severity of MR. For example in a study of
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FIGURE 3 | Measurements of leaflet geometry by 2D TTE.
119 patients with ischaemic or dilated cardiomyopathy, 48 (40%)
patients had S wave blunting without severe MR and 24 (20%)
had no MR at all (59).
The limitations of 2D echocardiographic assessment can
be mitigated by using an algorithm incorporating multiple
parameters to risk stratify patients and identify those in
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FIGURE 4 | 3D TOE reconstruction of the mitral annulus in systole (A) and diastole (B). Measurements of anteroposterior and Intercommisural diameters (C). An
example of the measurements of the mitral annulus obtained (D).
need of valvular intervention. In a study of 423 patients
wth chronic heart failure, patients with EROA < 0.2 cm2,
RVol < 30ml were identified as having low mortality
risk while those with EROA > 0.3 cm2 and Rvol >
45ml were high risk. For the intermediate group (EROA
0.2–0.29 cm2 and RVol 30–44ml), a regurgitant fraction
above and below 50% was found to be a threshold which
could divide patients into the high and low risk categories,
respectively (60).
The limitations of 2D echocardiography can also be
overcome by routine use of 3D color Doppler with multiplanar
reconstruction (MPR). The problem of non-hemispherical shape
can be surmounted by using biplane to measure VCW in
perpendicular views or by using multiplanar reconstruction
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FIGURE 5 | 2D TTE demonstrating papillary-fibrosa distance (A) & interpapillay distance (B).
to measure vena contracta area (VCA). While the threshold
for VCA severity remains to be clearly defined, 98% of sMR
patients with an EROA > 0.2 cm2 have a VCA of > 0.4
cm2, a figure which correlates closely with other measures of
severe regurgitation (17). 3D color Doppler can be used to
directly measure the EROA, and has been validated against other
measures on echocardiography and externally validated against
phase-encoded CMR (61). 3D values for EROA tend to be larger
than those calculated using the 2D color Doppler PISA method,
as demonstrated in Figure 7. The clinical impact of this under-
estimation using the 2D color Doppler method was emphasized
in a study of 111 pMR and 100 sMR patients, in which a third
of those patients with severe MR on 3D were mis-classified as
having non-severe MR by 2D EROA (62).
Role of CMR
RVol is most often calculated in CMR by measuring the
difference between LV stroke volume (from a stack of short
axis steady state free precession cine images) and aortic stroke
volume from phase-contrast velocity flow mapping in the aortic
sinus (Figure 8) (63). As internal validation, aortic stroke volume
should be within 5% of the pulmonary artery stroke volume in the
absence of other regurgitant valves or intracardiac shunts. The
advantage of CMR is that the calculated RVol is independent of
the number, shape or eccentricity of the regurgitant jet(s), their
duration through systole, and CMR requires no contrast agents
or ionizing radiation. The disadvantages are that phase-contrast
mapping can be affected by phase offset error, while irregular
cardiac rhythm, poor breath-holding, and basal slice selection
reduce the reliability of calculated LV stroke volume. There
is however, evidence that quantifying MR by CMR improves
reproducibility and may be a better arbiter of outcome than
echocardiography (64). Firstly, disagreement in the grading
of MR severity by echo and CMR is common. Of the 5
studies comparing CMR to 2D echo, there was moderate to
good agreement (r = 0.6–0.92) in only 26–66% patients when
categorizing MR as severe (65–69). Of the 4 studies comparing
CMR to 3D echo, agreement improved to 49–79% (62), but
there was considerable variation in results across studies (70–72).
Secondly, reproducibility in all studies is consistently better using
CMR than echo, whether by 2D or 3D (64). Thirdly, grading
by CMR has the potential to be a better predictor of patient
outcome, although data that shows improved prediction of LV
reverse remodeling (65) and of need for surgery and mortality
are limited to pMR only (73). More data are needed in sMR, not
only to validate markers of severity of sMR against outcomes but
also to define the potential role of tissue characterisation of the
LV in predicting outcome from intervention.
Summary Recommendations
Multiparametric TTE is the mainstay for quantifying sMR;
• There aremajor limitations of 2DTTE and TOE quantification
of sMR;
• 3D echo overcomes many of the limitations of 2D but
reproducibility is an issue;
• Quantification of sMR by CMR is more reproducible and may
be a better arbiter of outcome but further research is needed.
IMAGING TO FACILITATE INTERVENTION
Multimodality imaging plays a central role in predicting benefit
from intervention, including accurate quantification of sMR
relative to the degree of LV remodeling, and identification
of mitral valve characteristics that are more amenable to
successful intervention.
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FIGURE 6 | Clinical integration of the different imaging modalities.
Mitral Valve Surgery
Although mitral annuloplasty produces excellent long-term
results in pMR (74), this is not the case in sMR, where only
75% of patients are free of recurrent MR at 2 years (29). Trials
of surgical intervention for sMR have generally demonstrated
poor results, despite revascularisation and correction of the
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TABLE 2 | sMR assessed by qualitative and quantitative echocardiographic methods.
Number of patients
(% ischaemic)
Cut off values Predicted Outcome Reference
QUALITATIVE
Size of jet on color flow doppler 272 severe sMR (100%) >50% left atrial area Mean survival 676 ± 41 days
RR of mortality 1.84 (1.43–2.38)
(13)
35 moderate-severe (58%) Jet area > 4.5 cm2 1-year mortality 51% OR of 1-year
mortality 4.47 vs. mild/absent MR
(14)
QUANTITATIVE
MV E wave decel time VCW (by TTE) 98 sMR patients (100%)
336 severe sMR (57%)




Independent predictor of mortality
Combined end point of death, HF
hospitalization and transplant
(15) (16)
VCA (by 3D TOE) 259 moderate/ severe sMR (44%) > 0.39 cm2 Detection of severe sMR: Sensitivity
92%; Specificity 90%
(17)
EROA (by 3D TOE PISA) 259 moderate/ severe sMR (44%) > 0.24 cm2 Detection of severe sMR: Sensitivity
83%; Specificity 74%
(17)
EROA (by TTE PISA) 194 severe sMR (100%) > 0.20 cm2 Adjusted RR of mortality 2.23
(1.31–3.79)
(18)
EROA (by TTE PISA or doppler) 98 severe sMR (100%) 0.2 cm2 at rest
> 0.13 cm2 on exertion
Independent predictors of mortality (15)
RVol (by EROA/Doppler) 194 (100%) > 30ml Adjusted RR of mortality 2.05
(1.30–3.23)
(18)
sMR, Secondary MR; MV, Mitral Valve; HF, Heart Failure; VCW, Vena Contract Width; VCA, Vena Contracta Area; EROA, Effective Regurgitant Orifice Area; TTE, Transthoracic
Echocardiogram; TOE, Transoesophageal echocardiogram; RVol, Regurgitant Volume; RR, Risk Reduction; MR, Mitral Regurgitation.
MR. Concomitant MV surgery at the time of CABG did
not confer a survival advantage compared to CABG alone
(75, 76). Patients with severe sMR who were randomized
to valve repair or replacement had similar 2-year cumulative
mortality rates of 19 and 23%, respectively, with high rates of
recurrent MR in those undergoing repair (77). In patients with
moderate sMR, surgical correction at the time of CABG did
not improve LV remodeling, adverse event rates, hospitalization,
or survival (78). In contrast, the RIME study (the only study
using CMR for pre-operative assessment) demonstrated that
although surgical correction of sMR did not improve survival,
operated patients had improved functional capacity and LV
reverse remodeling (79).
Pre-operative characteristics that are associated with increased
failure rates on echo include more extreme LV remodeling (LV
end-diastolic diameter > 65mm) and greater distortion of the
MV apparatus (leaflet tenting height > 6mm) (22). Similar
conclusions were drawn in a prospective study using 3D TOE
and CMR, again identifying a combination of more extreme LV
remodeling (indexed LVESV> 45.4ml/m2) and greater tethering
(assessed by measurement of the posterior leaflet angle > 40.2◦)
as strongly associated with high likelihood of sMR recurrence
(29). The potential added value of CMR tissue characterisation
was demonstrated by the finding that sMR recurrence was more
likely in those with more extensive infarction (> 3 non-viable
LV segments or > 1 non-viable segment in the posterior wall)
(29). A full list of imaging predictors of sMR recurrence following
surgical annuloplasty are listed in Table 1.
Transcatheter Repair
While a number of devices are in development, transcatheter
edge-to-edge repair using MitraClip is currently the most
widely used device. Other devices such as Cardioband and
the Carillon mitral contour system have CE approval and
have shown promising results in reducing mitral regurgitant
volume (80, 81). In the Endovascular Edge-to-Edge Repair
(EVEREST II) trial, transcatheter mitral valve repair (TMVR)
using MitraClip was compared to mitral valve surgery. Amongst
75 sMR patients, TMVR was equivalent to surgery with respect
to the composite primary end-point of freedom from death,
surgery for mitral valve dysfunction and ≥ grade 3+ MR after
1 year (82).
Patient selection is one of the most important factors
determining success of TMVR as evidenced by the contrasting
outcomes of the COAPT (7) and MITRA-FR studies
(83) (Table 3).
Generally, those patients with a larger EROA, larger mitral
valve area (> 4 cm2), and smaller transmitral pressure gradient
(< 4 mmHg) have better outcomes following TMVR (84). Worse
outcomes are seen in patients with higher RV systolic pressure
(RVSP) (85), larger indexed left atrial volume (cut-off 67 ml/m2)
(86) and greater post-procedure sMR (87).
Pre-procedural assessment by CT is expected to increase
with growth of TMVR. The major advantages of CT
are accurate measurement of mitral annular dimensions,
which has implications for device sizing, landing zone,
determining risk of LV outflow tract (LVOT) obstruction, and
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FIGURE 7 | Difference between EROA derived from 2D TOE (A,B) calculated at 0.15 cm2 and EROA derived from 3D TOE (C,D) in the same patient calculated at
0.45 cm2.
delineation of mitral annular calcification, in whom TMVR
carries higher risk (88). 3D echo accomplishes these with
similar accuracy.
Intraprocedural 3D TOE is essential during all steps of TMVR
and is superior to 2D TOE (89). Post-procedure, assessment of
residual regurgitation can be performed using 3D color doppler.
In sMR patients, a post-procedure VCA reduction of > 50% is
associated with significant reduction in LA and LV volumes at 6
month follow up (90).
Summary Recommendations
There aremultiple validated pre-operative characteristics on echo
identifying likely outcome from surgical repair in sMR;
• Echo and CT both have an important role in the pre-procedure
work up for TMVR;
• Intraprocedural 3D TOE is critical to the success of TMVR and
superior to 2D TOE.
FUTURE DIRECTIONS—DEFINING THE
TARGET POPULATION
The conflicting MITRA-FR and COAPT studies have re-ignited
debate regarding patient selection in sMR. At the forefront of
this discussion are the imaging parameters used to assess the
severity of MR, LV size, and function and their relationship to
one another. Several have suggested that this is a consequence
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FIGURE 8 | (A) Volumetric assessment of LV/RV short axis stack using the detailed contouring method showing a dilated LV (LV volume 106 ml/m2 ) with mildly
impaired LVEF (49%). Calculated LV stroke volume (SV): 111ml, RV SV: 74ml. (B) Phase contrast aortic flow analysis showing a total forward volume of 74ml with no
significant regurgitation. Estimated MR volume based on RV/LV SV variation and volumes-derived SV and phase contrast aortic flow: 111–74 = 37ml.
TABLE 3 | Differences between COAPT and MITRA-FR study populations.
Differences between COAPT and MITRA-FR
COAPT MITRA-FR
Number of patients 614 304
Centers North America France
Study design MitraClip + GDMT vs.
GDMT alone
MitraClip + GDMT vs.
GDMT alone






all-cause death + HF
hospitalization at 12 m
EROA, mm2 (mean ± SD) 41 ± 15 31 ± 10
> 40 mm2 41% 16%
30–40 mm2 46% 32%
<30 mm2 14% 52%
LVEF, % (mean ± SD) 31 ± 9 33 ± 7
LVEDV, ml/m2 (mean ± SD) 101 ± 34 135 ± 35
Procedural complications 8.5% 14.6%
MR Grade ≥ 3+ at 12m 5% 17%
COAPT, Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy
for Heart Failure Patients with Functional Mitral Regurgitation; MITRA-FR, Percutaneous
Repair or Medical Treatment for SecondaryMitral Regurgitation; GDMT, Guideline Directed
Medical Therapy; EROA, Effective Regurgitant Orifice Area; LVEF, Left Ventricular Ejection
Fraction; LVEDV, Left Ventricular End Diastolic Volume; MR, Mitral Regurgitation; SD,
Standard Deviation.
of population heterogeneity, with two cohorts: those in whom
chronic heart failure and global LV remodeling is the primary
pathology and in whom there is a linear relationship between
LV dilatation and EROA for any given LVEF. Accordingly, the
degree of sMR is “proportionate” to the LV remodeling (with a
lower RVol), and these patients are most likely to benefit from
heart failure therapies. The contrasting cohort are those with
predominant MV valve abnormalities, in whom there is greater
regurgitation which is “disproportionate” to LV remodeling.
These patients are expected to respond more favorably to
mitral valve intervention (91–94). In support of this, subgroup
analysis of COAPT patients revealed that the hazard ratio of
effect of transcatheter repair crosses 1 as EROA/EDV decreases
(95). Others have argued that it is chiefly the haemodynamic
burden of sMR that determines benefit from percutaneous
mitral intervention, and that RVol and regurgitant fraction
(RF) may be more accurate measures (96). The problem with
either of these arguments is the ability of echo to measure
ventricular volumes, RVol or RF with sufficient accuracy, and
future work is needed to explore the potential role of CMR
in this regard.
CONCLUSION
sMR is common and mortality is high with and without
treatment. Medical and surgical therapies do not significantly
impact survival but TMVR may reduce mortality and heart
failure hospitalization. Assessment of the sMR jet and MV
apparatus by 2D and 3D TTE and TOE using a multiparametric
approach remain the foundation for assessment. There
are however limitations and CMR has the potential to
revolutionize the assessment of patients with sMR but is
currently underutilized in this field due to lack of research. The
role of CT is growing in sMR due to pre-procedural assessment
of the patient under consideration for TMVR.
AUTHOR CONTRIBUTIONS
All authors contributed to the writing and proofreading of
the article.
FUNDING
SM and HS are supported by the National Institute for Health
Research (NIHR) Oxford Biomedical Research Centre.
Frontiers in Cardiovascular Medicine | www.frontiersin.org 12 December 2020 | Volume 7 | Article 546279
Sharma et al. Multimodality Imaging Secondary Mitral Regurgitation
REFERENCES
1. Nishino S, Watanabe N, Kimura T, Enriquez-Sarano M, Nakama T, Furugen
M, et al. The course of ischemic mitral regurgitation in acute myocardial
infarction after primary percutaneous coronary intervention. Circ Cardiovasc
Imaging. (2016) 9:1–10. doi: 10.1161/CIRCIMAGING.116.004841
2. Blondheim DS, Jacobs LE, Kotler MN, Costacurta GA, Parry WR. Dilated
cardiomyopathy with mitral regurgitation: decreased survival despite a low
frequency of left ventricular thrombus. Am Heart J. (1991) 122:763–71.
doi: 10.1016/0002-8703(91)90523-K
3. Kusunose K, Obuchowski NA, GillinovM, Popovic ZB, Flamm SD, Griffin BP,
et al. Predictors of mortality in patients with severe ischemic cardiomyopathy
undergoing surgical mitral valve intervention. J Am Heart Assoc. (2017)
6:e007163. doi: 10.1161/JAHA.117.007163
4. Rossi A, Dini FL, Faggiano P, Agricola E, Cicoira M, Frattini S, et al.
Independent prognostic value of functional mitral regurgitation in patients
with heart failure. A quantitative analysis of 1256 patients with ischaemic
and non-ischaemic dilated cardiomyopathy. Heart. (2011) 97:1675–80.
doi: 10.1136/hrt.2011.225789
5. Eacts CS, Germany CH, Rosenhek R, France EL, Rodriguez D, Tornos P, et
al. ESC/EACTS guidelines for the management of valvular heart disease. Eur
Heart J. (2017) 38:2739–91.
6. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Fleisher
LA, et al. AHA/ACC focused update of the 2014 AHA/ACC guideline
for the management of patients with valvular heart disease: a report
of the American College of Cardiology/American Heart Association task
force on clinical practice guidelines. Circulation. (2017) 135:e1159–95.
doi: 10.1161/CIR.0000000000000503
7. Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, et al.
Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med.
(2018) 379:2307–18. doi: 10.1056/NEJMoa1806640
8. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-
SaranoM. Burden of valvular heart diseases: a population-based study. Lancet.
(2006) 368:1005–11. doi: 10.1016/S0140-6736(06)69208-8
9. Feinberg MS, Schwammenthal E, Shlizerman L, Porter A, Hod H, Freimark
D, et al. Prognostic significance of mild mitral regurgitation by color Doppler
echocardiography in acute myocardial infarction. Am J Cardiol. (2000)
86:903–7. doi: 10.1016/S0002-9149(00)01119-X
10. Dal-Bianco JP, Aikawa E, Bischoff J, Guerrero JL, Handschumacher MD,
Sullivan S, et al. Active adaptation of the tethered mitral valve: insights into
a compensatory mechanism for functional mitral regurgitation. Circulation.
(2009) 120:334–42. doi: 10.1161/CIRCULATIONAHA.108.846782
11. Chaput M, Handschumacher MD, Tournoux F, Hua L, Guerrero JL, Vlahakes
GJ, et al. Mitral leaflet adaptation to ventricular remodeling occurrence and
adequacy in patients with functional mitral regurgitation. Circulation. (2008)
118:845–52. doi: 10.1161/CIRCULATIONAHA.107.749440
12. Liu B, Edwards NC, Pennell D, Steeds RP. The evolving role of cardiac
magnetic resonance in primary mitral regurgitation: ready for prime time?
Eur Heart J Cardiovasc Imaging. (2019) 20:123–30. doi: 10.1093/ehjci/jey147
13. Koelling TM, Aaronson KD, Cody RJ, Bach DS, Armstrong WF. Prognostic
significance of mitral regurgitation and tricuspid regurgitation in patients
with left ventricular systolic dysfunction. Am Heart J. (2002) 144:524–9.
doi: 10.1067/mhj.2002.123575
14. Cioffi G, Tarantini L, De Feo S, Pulignano G, Del Sindaco D, Stefenelli C,
et al. Functional mitral regurgitation predicts 1-year mortality in elderly
patients with systolic chronic heart failure. Eur J Heart Fail. (2005) 7:1112–7.
doi: 10.1016/j.ejheart.2005.01.016
15. Lancellotti P, Troisfontaines P, Toussaint AC, Pierard LA. Prognostic
importance of exercise-induced changes in mitral regurgitation in patients
with chronic ischemic left ventricular dysfunction. Circulation. (2003)
108:1713–7. doi: 10.1161/01.CIR.0000087599.49332.05
16. Grayburn PA, Appleton CP, Demaria AN, Greenberg B, Lowes B, Oh J, et
al. Echocardiographic predictors of morbidity and mortality in patients with
advanced heart failure: the Beta-blocker Evaluation of Survival Trial (BEST). J
Am Coll Cardiol. (2005) 45:1064–71. doi: 10.1016/j.jacc.2004.12.069
17. Goebel B, Heck R, Hamadanchi A, Otto S, Doenst T, Jung C, et al. Vena
contracta area for severity grading in functional and degenerative mitral
regurgitation: a transoesophageal 3D colour Doppler analysis in 500 patients.
Eur Hear J. (2018) 19:639–46. doi: 10.1093/ehjci/jex056
18. Grigioni F, Enriquez-Sarano M, Zehr KJ, Bailey KR, Tajik AJ. Ischemic
mitral regurgitation: long-term outcome and prognostic implications
with quantitative Doppler assessment. Circulation. (2001) 103:1759–64.
doi: 10.1161/01.CIR.103.13.1759
19. Kongsaerepong V, Shiota M, Gillinov AM, Song JM, Fukuda S, McCarthy PM,
et al. Echocardiographic predictors of successful versus unsuccessful mitral
valve repair in ischemic mitral regurgitation. Am J Cardiol. (2006) 98:504–8.
doi: 10.1016/j.amjcard.2006.02.056
20. McGee EC, Gillinov AM, Blackstone EH, Rajeswaran J, Cohen G, Najam
F, et al. Recurrent mitral regurgitation after annuloplasty for functional
ischemic mitral regurgitation. J Thorac Cardiovasc Surg. (2004) 128:916–24.
doi: 10.1016/j.jtcvs.2004.07.037
21. Magne J, Pibarot P, Dagenais F, Hachicha Z, Dumesnil JG,
Sénéchal M. Preoperative posterior leaflet angle accurately
predicts outcome after restrictive mitral valve annuloplasty for
ischemic mitral regurgitation. Circulation. (2007) 115:782–91.
doi: 10.1161/CIRCULATIONAHA.106.649236
22. Gasser S, von Stumm M, Sinning C, Schaefer U, Reichenspurner H,
Girdauskas E. Can we predict failure of mitral valve repair? J Clin Med. (2019)
8:526. doi: 10.3390/jcm8040526
23. Bouma W, Lai EK, Levack MM, Shang EK, Pouch AM, Eperjesi TJ, et al.
Preoperative three-dimensional valve analysis predicts recurrent ischemic
mitral regurgitation after mitral annuloplasty. Ann Thorac Surg. (2016)
101:567–75. doi: 10.1016/j.athoracsur.2015.09.076
24. Braun J, van de Veire NR, Klautz RJM, Versteegh MIM, Holman ER,
Westenberg JJM, et al. Restrictive mitral annuloplasty cures ischemic
mitral regurgitation and heart failure. Ann Thorac Surg. (2008) 85:430–7.
doi: 10.1016/j.athoracsur.2007.08.040
25. Gelsomino S, Lorusso R, De Cicco G, Capecchi I, Rostagno C, Caciolli S, et
al. Five-year echocardiographic results of combined undersized mitral ring
annuloplasty and coronary artery bypass grafting for chronic ischaemic mitral
regurgitation. Eur Heart J. (2008) 29:231–40. doi: 10.1093/eurheartj/ehm468
26. Roshanali F, Mandegar MH, Yousefnia MA, Rayatzadeh H, Alaeddini F.
A prospective study of predicting factors in ischemic mitral regurgitation
recurrence after ring annuloplasty. Ann Thorac Surg. (2007) 84:745–9.
doi: 10.1016/j.athoracsur.2007.04.106
27. Lancellotti P, Tribouilloy C, Hagendorff A, Popescu BA, Edvardsen T, Pierard
LA, et al. Recommendations for the echocardiographic assessment of native
valvular regurgitation: an executive summary from the European Association
of Cardiovascular Imaging. EurHeart J Cardiovasc Imaging. (2013) 14:611–44.
doi: 10.1093/ehjci/jet105
28. Kron IL, Hung J, Overbey JR, Bouchard D, Gelijns AC, Moskowitz AJ, et al.
Predicting recurrent mitral regurgitation after mitral valve repair for severe
ischemicmitral regurgitation. J Thorac Cardiovasc Surg. (2015) 149:752–61.e1.
doi: 10.1016/j.jtcvs.2014.10.120
29. Glaveckaite S, Uzdavinyte-Gateliene E, Petrulioniene Z, Palionis D,
Valeviciene N, Kalinauskas G, et al. Predictors of ischaemic mitral
regurgitation recurrence in patients undergoing combined surgery: additional
value of cardiovascular magnetic resonance imaging
†
. Interact Cardiovasc
Thorac Surg. (2018) 27:222–8. doi: 10.1093/icvts/ivy054
30. Beaudoin J, Thai WE, Wai B, Handschumacher MD, Levine RA, Truong
QA. Assessment of mitral valve adaptation with gated cardiac computed
tomography: validation with three-dimensional echocardiography and
mechanistic insight to functional mitral regurgitation. Circ Cardiovasc
Imaging. (2013) 6:784–9. doi: 10.1161/CIRCIMAGING.113.000561
31. Chan KMJ, Wage R, Symmonds K, Rahman-Haley S, Mohiaddin RH, Firmin
DN, et al. Towards comprehensive assessment of mitral regurgitation using
cardiovascular magnetic resonance. J Cardiovascul Magnet Resonance. (2008)
10:61. doi: 10.1186/1532-429X-10-61
32. Stork A, Franzen O, Ruschewski H, Detter C, Müllerleile K, Bansmann PM,
et al. Assessment of functional anatomy of the mitral valve in patients with
mitral regurgitation with cine magnetic resonance imaging: comparison with
transesophageal echocardiography and surgical results. Eur Radiol. (2007)
17:3189–98. doi: 10.1007/s00330-007-0671-5
33. Levine RA, Weyman AE, Handschumacher MD. Three-dimensional
echocardiography: techniques and applications. Am J Cardiol. (1992)
69:H121–30. doi: 10.1016/0002-9149(92)90656-J
34. Levack MM, Jassar AS, Shang EK, Vergnat M, Woo YJ, Acker MA, et al.
Three-dimensional echocardiographic analysis of mitral annular dynamics:
Frontiers in Cardiovascular Medicine | www.frontiersin.org 13 December 2020 | Volume 7 | Article 546279
Sharma et al. Multimodality Imaging Secondary Mitral Regurgitation
implication for annuloplasty selection. Circulation. (2012) 126(11 Suppl
1):S183–8. doi: 10.1161/CIRCULATIONAHA.111.084483
35. Daimon M, Saracino G, Fukuda S, Koyama Y, Kwan J, Song JM, et al.
Dynamic change of mitral annular geometry and motion in ischemic mitral
regurgitation assessed by a computerized 3D echo method. Echocardiography.
(2010) 27:1069–77. doi: 10.1111/j.1540-8175.2010.01204.x
36. Kaji S, Nasu M, Yamamuro A, Tanabe K, Nagai K, Tani T, et al. Annular
geometry in patients with chronic ischemic mitral regurgitation: three-
dimensional magnetic resonance imaging study. Circulation. (2005) 112:I-
409–I-414. doi: 10.1161/CIRCULATIONAHA.104.525246
37. Mihalatos DG, Joseph S, Gopal A, Bercow N, Toole R, Passick M, et
al. Mitral annular remodeling with varying degrees and mechanisms of
chronic mitral regurgitation. J Am Soc Echocardiogr. (2007) 20:397–404.
doi: 10.1016/j.echo.2006.09.015
38. Watanabe N, Ogasawara Y, Yamaura Y, Wada N, Kawamoto T, Toyota E,
et al. Mitral annulus flattens in ischemie mitral regurgitation: Geometric
differences between inferior and anterior myocardial infarction - a real-
time 3-dimensional echocardiographic study. Circulation. (2005) 112(Suppl.
9):458–62. doi: 10.1161/CIRCULATIONAHA.104.524595
39. Ring L, Dutka DP, Boyd J, Parker K, Wendler O, Monaghan MJ, et al.
The normal mitral valve annulus in humans defined using 3-dimensional
transesophageal echocardiography. JACC Cardiovasc Imag. (2018) 11:510–2.
doi: 10.1016/j.jcmg.2017.05.017
40. Weir-McCall JR, Blanke P, Naoum C, Delgado V, Bax JJ, Leipsic J. Mitral valve
imaging with CT: relationship with transcatheter mitral valve interventions.
Radiology. (2018) 288:638–55. doi: 10.1148/radiol.2018172758
41. Gorman JH, Gorman RC, Plappert T, Jackson BM, Hiramatsu Y, St. John-
Sutton MG, et al. Infarct size and location determine development of mitral
regurgitation in the sheep model. J Thorac Cardiovasc Surg. (1998) 115:615–
22. doi: 10.1016/S0022-5223(98)70326-5
42. Kumanohoso T, Otsuji Y, Yoshifuku S, Matsukida K, Koriyama C,
Kisanuki A, et al. Mechanism of higher incidence of ischemic mitral
regurgitation in patients with inferior myocardial infarction: quantitative
analysis of left ventricular and mitral valve geometry in 103 patients with
prior myocardial infarction. J Thorac Cardiovasc Surg. (2003) 125:135–43.
doi: 10.1067/mtc.2003.78
43. Krawczyk-Ozóg A, Hołda MK, Bolechała F, Siudak Z, Sorysz D, Dudek D, et
al. Anatomy of the mitral subvalvular apparatus. J Thorac Cardiovasc Surg.
(2018) 155:2002–10. doi: 10.1016/j.jtcvs.2017.12.061
44. Krawczyk-Ozóg A, Hołda MK, Sorysz D, Koziej M, Siudak Z, Dudek D, et al.
Morphologic variability of the mitral valve leaflets. J Thorac Cardiovasc Surg.
(2017) 154:1927–35. doi: 10.1016/j.jtcvs.2017.07.067
45. Okayama S, Uemura S, Soeda T, Onoue K, Somekawa S, Ishigami KI, et al.
Clinical significance of papillary muscle late enhancement detected via cardiac
magnetic resonance imaging in patients with single old myocardial infarction.
Int J Cardiol. (2011) 146:73–9. doi: 10.1016/j.ijcard.2010.04.037
46. Chinitz JS, Chen D, Goyal P, Wilson S, Islam F, Nguyen T, et al. Mitral
apparatus assessment by delayed enhancement CMR: relative impact of infarct
distribution on mitral regurgitation. JACC Cardiovasc Imaging. (2013) 6:220–
34. doi: 10.1016/j.jcmg.2012.08.016
47. Tcheng JE, Jackman Jr. JD, Nelson CL, Gardner LH, Smith LR, Rankin JS, et
al. Outcome of patients sustaining acute ischemic mitral regurgitation
during myocardial infarction. Ann Intern Med. (1992) 117:18–24.
doi: 10.7326/0003-4819-117-1-18
48. Thompson CR, Buller CE, Sleeper LA, Antonelli TA, Webb JG, Jaber WA,
et al. Cardiogenic shock due to acute severe mitral regurgitation complicating
acute myocardial infarction: a report from the SHOCK trial registry. J Am Coll
Cardiol. (2000) 36(3 Suppl. A):1104–9. doi: 10.1016/S0735-1097(00)00846-9
49. Dziadzko V, Clavel MA, Dziadzko M, Medina-Inojosa JR, Michelena
H, Maalouf J, et al. Outcome and undertreatment of mitral
regurgitation: a community cohort study. Lancet. (2018) 391:960–9.
doi: 10.1016/S0140-6736(18)30473-2
50. Bertini M, Ng ACT, Antoni ML, Nucifora G, Ewe SH, Auger D, et al. Global
Longitudinal Strain Predicts Long-Term Survival in Patients With Chronic
Ischemic Cardiomyopathy. (2012) Available online at: http://ahajournals.org
(accessed Mar 26, 2020).
51. Gardner BI, Bingham SE, Allen MR, Blatter DD, Anderson JL. Cardiac
magnetic resonance versus transthoracic echocardiography for the assessment
of cardiac volumes and regional function after myocardial infarction:
an intrasubject comparison using simultaneous intrasubject recordings.
Cardiovasc Ultrasound. (2009) 7:38. doi: 10.1186/1476-7120-7-38
52. Matthews J, Boniface NC, Mikolich BM, Lisko J, Ronald Mikolich J.
Assessment of left ventricular volume overload: comparison of 2-D
echo and cardiac MRI. J Cardiovasc Magn Reson. (2014) 16(S1):P245.
doi: 10.1186/1532-429X-16-S1-P245
53. Hoffmann R, Barletta G, Von Bardeleben S, Vanoverschelde JL, Kasprzak
J, Greis C, et al. Analysis of left ventricular volumes and function:
a multicenter comparison of cardiac magnetic resonance imaging, cine
ventriculography, and unenhanced and contrast-enhanced two-dimensional
and three-dimensional echocardiography. J Am Soc Echocardiogr. (2014)
27:292–301. doi: 10.1016/j.echo.2013.12.005
54. Namazi F, van der Bijl P, Kamperidis V, van Wijngaarden S, Marsan
NA, Vahanian A, et al. Regurgitant volume and left ventricular end-
diastolic volume ratio: a new prognostic indice in patients with
secondary mitral regurgitation? J Am Coll Cardiol. (2019) 73:1955.
doi: 10.1016/S0735-1097(19)32561-6
55. Piérard LA, Lancellotti P. The role of ischemic mitral regurgitation in the
pathogenesis of acute pulmonary edema. N Engl J Med. (2004) 351:1627–34.
doi: 10.1056/NEJMoa040532
56. Cavalcante JL, Obuchowski N, Saleh Q, Popovic Z, Desai MY, Flamm S,
et al. Global left ventricular remodeling, extent of inferior wall infarct,
and mitral valve geometry are important predictors of mitral regurgitation
severity than total infarct size in advanced ischemic cardiomyopathy. J
CardiovascMagn Reson. (2014) 16(Suppl 1):P229. doi: 10.1186/1532-429X-16-
S1-P229
57. Puntmann VO, Carr-White G, Jabbour A, Yu CY, Gebker R, Kelle S,
et al. Native T1 and ECV of noninfarcted myocardium and outcome in
patients with coronary artery disease. J Am Coll Cardiol. (2018) 71:766–78.
doi: 10.1016/j.jacc.2017.12.020
58. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA,
et al. AHA/ACC guideline for the management of patients with valvular
heart disease: Executive summary: a report of the American College of
Cardiology/American Heart Association task force on practice guidelines.
Circulation. (2014) 129:2440–92. doi: 10.1161/CIR.0000000000000029
59. Dini FL, Dell’Anna R, Micheli A, Michelassi C, Rovai D. Impact
of blunted pulmonary venous flow on the outcome of patients with
left ventricular systolic dysfunction secondary to either ischemic or
idiopathic dilated cardiomyopathy. Am J Cardiol. (2000) 85:1455–60.
doi: 10.1016/S0002-9149(00)00794-3
60. Bartko PE, Arfsten H, Heitzinger G, Pavo N, Toma A, Strunk
G, et al. A unifying concept for the quantitative assessment of
secondary mitral regurgitation. J Am Coll Cardiol. (2019) 73:2506–17.
doi: 10.1016/j.jacc.2019.02.075
61. Marsan NA, Westenberg JJM, Ypenburg C, Delgado V, van Bommel
RJ, Roes SD, et al. Quantification of functional mitral regurgitation by
real-time 3D echocardiography. comparison with 3D velocity-encoded
cardiac magnetic resonance. JACC Cardiovasc Imaging. (2009) 2:1245–52.
doi: 10.1016/j.jcmg.2009.07.006
62. Choi J, Heo R, Hong GR, Chang HJ, Sung JM, Shin SH, et al.
Differential effect of 3-dimensional color doppler echocardiography
for the quantifcation of mitral regurgitation according to the severity
and characteristics. Circ Cardiovasc Imaging. (2014) 7:535–44.
doi: 10.1161/CIRCIMAGING.113.001457
63. Kramer CM, Barkhausen J, Bucciarelli-Ducci C, Flamm SD, Kim RJ,
Nagel E. Standardized cardiovascular magnetic resonance imaging
(CMR) protocols: 2020 update. J Cardiovasc Magn Reson. (2020) 22:17.
doi: 10.1186/s12968-020-00607-1
64. Uretsky S, Argulian E, Narula J, Wolff SD. Use of cardiac magnetic resonance
imaging in assessing mitral regurgitation: current evidence. J Am Coll Cardiol.
(2018) 71:547–63. doi: 10.1016/j.jacc.2017.12.009
65. Uretsky S, Gillam L, Lang R, Chaudhry FA, Argulian E, Supariwala A,
et al. Discordance Between Echocardiography and MRI in the Assessment
of Mitral Regurgitation Severity a Prospective Multicenter Trial. (2015).
doi: 10.1016/j.jacc.2014.12.047
66. Fujita N, Chazouilleres AF, Hartiala JJ, O’sullivan M, Heidenreich P, Kaplan
JD, et al. Quantification of mitral regurgitation by velocity-encoded cine
Frontiers in Cardiovascular Medicine | www.frontiersin.org 14 December 2020 | Volume 7 | Article 546279
Sharma et al. Multimodality Imaging Secondary Mitral Regurgitation
nuclear magnetic resonance imaging. J Am Coll Cardiol. (1994) 23:951–8.
doi: 10.1016/0735-1097(94)90642-4
67. Gelfand E V, Hughes S, Hauser TH, Yeon SB, Goepfert L, Kissinger KV, et
al. Severity of mitral and aortic regurgitation as assessed by cardiovascular
magnetic resonance: optimizing correlation with Doppler echocardiography.
J Cardiovasc Magn Reson. (2006) 8:503–7. doi: 10.1080/10976640600604856
68. Lopez-Mattei JC, Ibrahim H, Shaikh KA, Little SH, Shah DJ, Maragiannis
D, et al. Comparative assessment of mitral regurgitation severity by
transthoracic echocardiography and cardiac magnetic resonance using an
integrative and quantitative approach. Am J Cardiol. (2016) 117:264–70.
doi: 10.1016/j.amjcard.2015.10.045
69. Sachdev V, HannoushH, Sidenko S, Saba SG, Sears-Rogan P, BandettiniWP, et
al. Are echocardiography and CMR really discordant in mitral regurgitation?
JACC Cardiovasc Imag. (2017) 10:823–4. doi: 10.1016/j.jcmg.2016.
08.007
70. Thavendiranathan P, Liu S, Datta S, Rajagopalan S, Ryan T, Igo SR, et
al. Quantification of chronic functional mitral regurgitation by automated
3-dimensional peak and integrated proximal isovelocity surface area
and stroke volume techniques using real-time 3-dimensional volume
color Doppler echocardiography: in vitro and clinical validation. Circ
Cardiovasc Imaging. (2013) 6:125–33. doi: 10.1161/CIRCIMAGING.112.
980383
71. Shanks M, Siebelink HMJ, Delgado V, Van De Veire NRL, Ng ACT, Sieders
A, et al. Quantitative assessment of mitral regurgitation comparison
between three-dimensional transesophageal echocardiography and
magnetic resonance imaging. Circ Cardiovasc Imaging. (2010) 3:694–700.
doi: 10.1161/CIRCIMAGING.110.947176
72. Heo R, Son JW, Hartaighó B, Chang HJ, Kim YJ, Datta S, et al. Clinical
implications of three-dimensional real-time color doppler transthoracic
echocardiography in quantifying mitral regurgitation: a comparison with
conventional two-dimensional methods. J Am Soc Echocardiogr. (2017)
30:393–403.e7. doi: 10.1016/j.echo.2016.12.010
73. Penicka M, Vecera J, Mirica DC, Kotrc M, Kockova R, Van Camp G.
Prognostic implications of magnetic resonance-derived quantification in
asymptomatic patients with organic mitral regurgitation: comparison with
doppler echocardiography-derived integrative approach. Circulation. (2018)
137:1349–60. doi: 10.1161/CIRCULATIONAHA.117.029332
74. David TE, Armstrong S, McCrindle BW, Manlhiot C. Late outcomes of mitral
valve repair for mitral regurgitation due to degenerative disease. Circulation.
(2013) 127:1485–92. doi: 10.1161/CIRCULATIONAHA.112.000699
75. Mihaljevic T, Lam BK, Rajeswaran J, Takagaki M, Lauer MS, Gillinov AM,
et al. Impact of mitral valve annuloplasty combined with revascularization
in patients with functional ischemic mitral regurgitation. J Am Coll Cardiol.
(2007) 49:2191–201. doi: 10.1016/j.jacc.2007.02.043
76. Castleberry AW, Williams JB, Daneshmand MA, Honeycutt
E, Shaw LK, Samad Z, et al. Surgical revascularization is
associated with maximal survival in patients with ischemic mitral
regurgitation: a 20-year experience. Circulation. (2014) 129:2547–56.
doi: 10.1161/CIRCULATIONAHA.113.005223
77. Goldstein D, Moskowitz AJ, Gelijns AC, Ailawadi G, Parides MK, Perrault
LP, et al. Two-year outcomes of surgical treatment of severe ischemic mitral
regurgitation. N Engl J Med. (2016) 374–53. doi: 10.1056/NEJMoa1512913
78. Michler RE, Smith PK, Parides MK, Ailawadi G, Thourani V, Moskowitz AJ,
et al. Two-year outcomes of surgical treatment of moderate ischemic mitral
regurgitation. N Engl J Med. (2016) 374:1932–41.
79. Chan KMJ, Punjabi PP, Flather M, Wage R, Symmonds K, Roussin I, et al.
Coronary artery bypass surgery with or without mitral valve annuloplasty
in moderate functional ischemic mitral regurgitation: final results of the
Randomized Ischemic Mitral Evaluation (RIME) trial. Circulation. (2012)
126:2502–10. doi: 10.1161/CIRCULATIONAHA.112.143818
80. Messika-Zeitoun D, Nickenig G, Latib A, Kuck KH, Baldus S, Schueler R,
et al. Transcatheter mitral valve repair for functional mitral regurgitation
using the Cardioband system: 1 year outcomes. Eur Heart J. (2019) 40:466–72.
doi: 10.1093/eurheartj/ehy424
81. Witte KK, Lipiecki J, Siminiak T, Meredith IT, Malkin CJ, Goldberg SL,
et al. The REDUCE FMR trial: a randomized sham-controlled study of
percutaneous mitral annuloplasty in functional mitral regurgitation. JACC
Hear Fail. (2019) 7:945–55. doi: 10.1016/j.jchf.2019.06.011
82. Feldman T, Foster E, Glower DD, Kar S, RinaldiMJ, Fail PS, et al. Percutaneous
repair or surgery for mitral regurgitation. N Engl J Med. (2011) 364:1395–406.
doi: 10.1056/NEJMoa1009355
83. Obadia J-F, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, et al.
Percutaneous repair or medical treatment for secondary mitral regurgitation.
N Engl J Med. (2018) 379:2297–306. doi: 10.1056/NEJMoa1805374
84. Hahn RT. Transcathether valve replacement and valve repair: review of
procedures and intraprocedural echocardiographic imaging. Circ Res. (2016)
119:341–56. doi: 10.1161/CIRCRESAHA.116.307972
85. Asch FM, Grayburn PA, Siegel RJ, Kar S, Lim DS, Zaroff JG, et al.
Echocardiographic outcomes after transcatheter leaflet approximation in
patients with secondary mitral regurgitation: the COAPT trial. J Am Coll
Cardiol. (2019) 74:2969–79. doi: 10.1016/j.jacc.2019.09.017
86. Baldi C, Citro R, Silverio A, Di Maio M, De Rosa R, Bonadies D, et al.
Predictors of outcome in heart failure patients with severe functional mitral
regurgitation undergoing MitraClip treatment. Int J Cardiol. (2019) 284:50–8.
doi: 10.1016/j.ijcard.2018.10.055
87. Orban M, Orban M, Lesevic H, Braun D, Deseive S, Sonne C, et al. Predictors
for long-term survival after transcatheter edge-to-edge mitral valve repair. J
Interv Cardiol. (2017) 30:226–33. doi: 10.1111/joic.12376
88. Guerrero M, Dvir D, Himbert D, Urena M, Eleid M, Wang DD,
et al. Transcatheter mitral valve replacement in native mitral valve
disease with severe mitral annular calcification: results from the first
multicenter global registry. JACC Cardiovasc Interv. (2016) 9:1361–71.
doi: 10.1016/j.jcin.2016.04.022
89. Altiok E, Becker M, Hamada S, Reith S, Marx N, Hoffmann R. Optimized
guidance of percutaneous edge-to edge repair of the mitral valve using
real-time 3-D transesophageal echocardiography. Clin Res Cardiol. (2011)
100:675–81. doi: 10.1007/s00392-011-0296-1
90. Altiok E, Hamada S, Brehmer K, Kuhr K, Reith S, Becker M, et al. Analysis
of procedural effects of percutaneous edge-to-edge mitral valve repair by
2D and 3D echocardiography. Circ Cardiovasc Imaging. (2012) 5:748–55.
doi: 10.1161/CIRCIMAGING.112.974691
91. Grayburn PA, Sannino A, Packer M. Proportionate and disproportionate
functional mitral regurgitation: a new conceptual framework that reconciles
the results of theMITRA-FR andCOAPT trials. JACCCardiovasc Imag. (2019)
12:353–62. doi: 10.1016/j.jcmg.2018.11.006
92. Packer M, Grayburn PA. Contrasting effects of pharmacological, procedural,
and surgical interventions on proportionate and disproportionate functional
mitral regurgitation in chronic heart failure. Circulation. (2019) 140:779–89.
doi: 10.1161/CIRCULATIONAHA.119.039612
93. Gaasch WH, Meyer TE. Secondary mitral regurgitation (part 1):
Volumetric quantification and analysis. Heart. (2018) 104:634–8.
doi: 10.1136/heartjnl-2017–312001
94. GaaschWH,Meyer TE. Secondary mitral regurgitation (part 2): Deliberations
on mitral surgery and transcatheter repair. Heart. (2018) 104:639–43.
doi: 10.1136/heartjnl-2017–312002
95. Packer M, Grayburn PA. New evidence supporting a novel conceptual
framework for distinguishing proportionate and disproportionate
functional mitral regurgitation. JAMA Cardiol. (2020) 5:469–75.
doi: 10.1001/jamacardio.2019.5971
96. Hahn RT. Disproportionate emphasis on proportionate mitral regurgitation -
are there better measures of regurgitant severity? JAMACardiol. (2020) 5:377–
9. doi: 10.1001/jamacardio.2019.6235
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
The handling editor declared a past co-authorship with the authors RS and SM.
Copyright © 2020 Sharma, Liu, Mahmoud-Elsayed, Myerson and Steeds. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Cardiovascular Medicine | www.frontiersin.org 15 December 2020 | Volume 7 | Article 546279
